DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 70-184

Biocraft Laboratories, Inc.
Attention: Mr. Harvey Richards
92 Route 46
P.O. Box 200
Elmwood Park, NJ 70407

JUL 29 [illegible]

Dear Mr. Richards:

Reference is made to your abbreviated new drug application dated November 26, 1984, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Metoclopramide Hydrochloride Tablets, 10 mg.

Reference is also made to your communications of March 1, 1985, June 21, 1985, June 25, 1985, July 3, 1985, July 15, 1985, and July 23, 1985.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved.

Any significant change in the conditions outlined in this abbreviated application requires an approved supplemental application before the change may be made, except for changes made in conformance with other provisions of Section 314.8 of the new drug regulations.

Postmarketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80 and 314.81.

This Administration should be advised of any change in the marketing status of this drug.

For Initial Campaigns: We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your immediate advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Advertising and Labeling (HFN-240). Please do not use Form FD-2253 for this initial submission.

For Subsequent Campaigns: We call your attention to Regulation 21 CFR 310.300 (b)(3) which requires that materials for any subsequent advertising or promotional campaign, at the time of their initial use, be submitted to our Division of Drug Advertising and Labeling (HFN-240) with a completed Form FD-2253. A copy of Form FD-2253 is enclosed for your convenience.

The enclosures summarize the conditions relating to the approval of this application.

Sincerely yours,

Marvin Seife

Marvin Seife, M.D.
Director
Division of Generic Drugs
Office of Drug Standards